Tacrolimus dry powder inhalation (TFF Pharmaceuticals)

他克莫司干粉吸入剂 (TFF Pharmaceuticals)

Report date: 2026/03/04 20:01:44

Base Information

Drug NameTacrolimus dry powder inhalation (TFF Pharmaceuticals)
Drug Alias NameTac-Lac Inhalation PowderInhaled tacrolimusTacrolimus inhalation powderTFF TACTFF TAC-LAC
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCalcineurin inhibitorsCytokines inhibitorsImmunosuppressants +[5] 
TargetsCalcineurinCytokinesBone morphogenetic protein receptor type-2
Therapy Area/IndicationsRejection of lung transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTff Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTff Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsRejection of lung transplantation

Other Information

ATC CodeN/A
Related LinksN/A